Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 49, 2011, Pages 19629-19634

  Lee, Ju Hee ^a   Choy, Megan L ^a   Ngo, Lang ^a   Venta Perez, Gisela ^a   Marks, Paul A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

H2AX; Checkpoint kinase 2; Histone deacetylases

Indexed keywords

7 HYDROXYSTAUROSPORINE; AZD 7762; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CHIR 124; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; ROMIDEPSIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE G2 PHASE; CELL DEATH; CHROMATID; CHROMOSOME; CHROMOSOME ABERRATION; DNA DAMAGE; DRUG ACTIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MITOSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; SENSITIVITY ANALYSIS;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; CELLS, CULTURED; DNA DAMAGE; DRUG RESISTANCE; FIBROBLASTS; FORESKIN; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; MALE; MICE; PROTEIN KINASES; QUINOLINES; QUINUCLIDINES; RNA INTERFERENCE; SPLEEN; STAUROSPORINE; THIOPHENES; UREA;

EID: 83755195245     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117544108     Document Type: Article

References (31)

1. Ma X, Ezzeldin HH, Diasio RB (2009) Histone deacetylase inhibitors: Current status and overview of recent clinical trials. Drugs 69:1911-1934.
2. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem 107:600-608.
3. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90. (Pubitemid 46087907)
4. Duvic M, Vu J (2007) Vorinostat: A new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16:1111-1120. (Pubitemid 47074165)
5. Grant C, et al. (2010) Romidepsin: A new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10:997-1008.
6. Mercurio C, Minucci S, Pelicci PG (2010) Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 62:18-34.
7. Kelly WK, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931. (Pubitemid 46218695)
8. Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325:834-840.
9. Ungerstedt JS, et al. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 102:673-678. (Pubitemid 40282724)
10. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA (2010) Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc Natl Acad Sci USA 107:14639-14644.
11. Kondo S, Perrimon N (2011) A genome-wide RNAi screen identifies core components of the G2-M DNA damage checkpoint. Sci Signal 4:rs1.
12. Chen Z, et al. (2003) Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2:543-548.
13. Bucher N, Britten CD (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98:523-528. (Pubitemid 351214533)
14. Liu Q, et al. (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14:1448-1459. (Pubitemid 30421838)
15. Löbrich M, Jeggo PA (2007) The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer 7:861-869. (Pubitemid 350006255)
16. Hartwell L (1992) Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71:543-546.
17. Yamauchi T, Keating MJ, Plunkett W (2002) UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther 1:287-294.
18. Carrassa L, Damia G (2011) Unleashing Chk1 in cancer therapy. Cell Cycle 10:2121-2128.
19. Zabludoff SD, et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther 7:2955-2966.
20. Tse AN, et al. (2007) CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin Cancer Res 13:591-602. (Pubitemid 46225366)
21. Xu H, et al. (2010) Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G(1) checkpoint-defective neuroblastoma. Int J Cancer 129:1953-1962.
22. Sausville EA, et al. (2001) Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19:2319-2333. (Pubitemid 32366984)
23. Kortmansky J, et al. (2005) Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol 23:1875-1884. (Pubitemid 46211365)
24. Hotte SJ, et al. (2006) Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: A Princess Margaret Hospital Phase II Consortium study. Ann Oncol 17:334-340. (Pubitemid 43160126)
25. Kummar S, et al. (2010) A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. Cancer Chemother Pharmacol 65:383-389.
26. Cheng H, Merika E, Syrigos KN, Saif MW (2011) Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP 12:334-338.
27. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243.
28. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci USA 103:15540-15545. (Pubitemid 44625628)
29. Butler LM, et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA 99:11700-11705. (Pubitemid 34994462)
30. Richon VM, et al. (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007. (Pubitemid 28135844)
31. Jayachandran G, Ueda K, Wang B, Roth JA, Ji L (2010) NPRL2 sensitizes human nonsmall cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS ONE 5:e11994.